Claims
- 1. A shaped body comprising:
a first segment comprising a polymerizable matrix and an inorganic filler; and in contact with at least a portion of the first segment, a second segment comprising an inorganic material having substantially uniform macro-, meso- and microporosity together with a pore volume of at least about 30%.
- 2. The shaped body of claim lwherein the inorganic material comprises calcium phosphate.
- 3. The shaped body of claim 1 wherein the pore volume of the inorganic material is at least about 50%.
- 4. The shaped body of claim 1 wherein the pore volume of the inorgaric material is at least about 70%.
- 5. The shaped body of claim 1 wherein the pore volume of the inorganic material is at least about 90%.
- 6. A composite body having at least two portions:
a first portion comprising the oxidation-reaction product of a blend comprising
at least one metal cation; at least one oxidizing agent; and at least one precursor anion oxidizable by said oxidizing agent to form an oxoanion; the second portion being imbibed into the first portion.
- 7. The composite body of claim 6 wherein the second portion is polymerized.
- 8. The composite body of claim 6 wherein the second portion is selected from the group consisting of polycaprolactones, polyglycolic acid, poly-L-lactic acid, polysulfones, polyolefins, polyvinyl alcohol, polyalkenoics, polyacrylic acids, and polyesters.
- 9. A composite body for drug delivery comprising:
a first portion comprising the oxidation-reaction product of a blend comprising
at least one metal cation; at least one oxidizing agent; and at least one precursor anion oxidizable by said oxidizing agent to form an oxoanion; a second, resorbable portion imbibed into the first portion; and a medicament.
- 10. The composite shaped body of claim 9 wherein the medicament is absorbed into the solid composite body.
- 11. The composite shaped body of claim 9 wherein the medicament is a growth hormone, antibiotic material, proteins, cell signaling material, steroids, analgesics, or fertility drugs.
- 12. A shaped body comprising:
a first portion comprised of an inorganic material having substantially uniform macro-, meso- and microporosity together with a pore volume of at least about 30%; and a second portion that contacts at least a portion of the first portion, wherein the second portion is comprised of a powder.
- 13. The shaped body of claim 12 wherein the powder is L-lactic acid.
- 14. A shaped body comprising:
a first portion comprised of an inorganic material having substantially uniform macro-, meso- and microporosity together with a pore volume of at least about 30%; and a second portion that contacts at least a portion of the first portion, wherein the first portion is a hollow sleeve.
- 15. The shaped body of claim 14 wherein the second portion is a graft material.
- 16. The shaped body of claim 14 wherein the second portion is a hardenable fluid material.
- 17. The shaped body of claim 16 wherein the fluid material is a liquid, paste, putty or gel.
- 18. The shaped body of claim 16 wherein the fluid material is polymerizable.
- 19. The shaped body of claim 16 wherein the fluid material is acrylic.
- 20. The shaped body of claim 14 wherein the outer surface of the hollow sleeve includes a plurality of orifices.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation-in-part of U.S. application Ser. No. 09/373,796, the contents of which are incorporated herein by reference in their entirety.
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
09373796 |
Aug 1999 |
US |
Child |
10165629 |
Jun 2002 |
US |